Invizius Secures £950K to Revolutionize Dialysis Treatment
September 24, 2024, 3:31 pm
Location: United Kingdom, Scotland, Motherwell
Employees: 11-50
Founded date: 2018
Total raised: $9.31M
In the heart of Edinburgh, a biotech company is on the brink of a breakthrough. Invizius has raised £950,000 in funding, a crucial step toward transforming dialysis treatment. This funding round, led by Mercia Ventures, is a beacon of hope for patients battling kidney issues.
Founded in 2018 as a spin-out from the University of Edinburgh, Invizius is not just another biotech firm. It’s a lifeline for those on dialysis. The company is developing H-Guard, a product designed to tackle the inflammatory responses that often plague dialysis patients. These responses can lead to severe complications, including damage to vital organs and the cardiovascular system.
The recent funding will propel Invizius into the next phase of clinical trials for H-Guard. This product is particularly aimed at continuous renal replacement therapy (CRRT), a type of dialysis used in intensive care units for patients with acute kidney injury. The stakes are high. Dialysis is a necessary evil for many, but it often comes with a host of complications. H-Guard seeks to change that narrative.
The immune system can be a double-edged sword. When blood comes into contact with the dialysis machine, it often reacts as if it’s encountering a foreign invader. This reaction can lead to inflammation, a response that can be life-threatening. H-Guard acts as a shield, coating the surfaces of the dialysis machine to prevent this immune response. It’s like putting on armor before entering battle.
Earlier this year, Invizius conducted a ‘First in Human’ study. The results were promising. The study demonstrated H-Guard’s safety and tolerability, along with encouraging biomarker data. This is a crucial milestone. It’s the first step in a long journey toward regulatory approval and widespread use.
The latest funding brings Invizius’s total raised to over £13 million. This is no small feat. It reflects the confidence investors have in the company’s vision and technology. The support from Calculus Capital, Syensqo, the University of Edinburgh’s Old College Capital, and Scottish Enterprise underscores the collaborative spirit of the Scottish biotech ecosystem.
Looking ahead, Invizius is gearing up for a Series B investment round early next year. This is where the stakes get even higher. The company aims to expand its research and development efforts, exploring additional benefits of H-Guard for patients. The potential is vast. If successful, H-Guard could redefine the standard of care for dialysis patients.
The urgency of this mission cannot be overstated. Dialysis can significantly reduce life expectancy. For many patients, it’s a matter of survival. The recent trials have shown that H-Guard has the potential to make a real difference. It’s not just about extending life; it’s about improving the quality of life.
Invizius’s journey is a testament to innovation in healthcare. The company is not just chasing profits; it’s pursuing a noble cause. The team, led by CEO Magnus Nicolson, is driven by a desire to save lives. Their commitment is palpable. Each trial, each study, is a step closer to a solution that could alleviate suffering for countless individuals.
The landscape of dialysis treatment is changing. H-Guard is at the forefront of this transformation. It represents hope for patients who have long endured the harsh realities of dialysis. The technology is not just a product; it’s a promise of better days ahead.
As Invizius prepares for its next clinical trials, the eyes of the medical community are watching closely. The implications of H-Guard extend beyond individual patients. They could reshape the entire approach to dialysis treatment. This is a pivotal moment in the field of nephrology.
In conclusion, Invizius’s recent funding is more than just a financial boost. It’s a lifeline for patients in need. The company’s innovative approach to addressing the challenges of dialysis is commendable. With H-Guard, Invizius is not just aiming to improve treatment; it’s striving to change lives. The journey is just beginning, but the destination is clear: a future where dialysis is safer and more effective. The road ahead may be long, but with each step, Invizius is paving the way for a brighter tomorrow.
Founded in 2018 as a spin-out from the University of Edinburgh, Invizius is not just another biotech firm. It’s a lifeline for those on dialysis. The company is developing H-Guard, a product designed to tackle the inflammatory responses that often plague dialysis patients. These responses can lead to severe complications, including damage to vital organs and the cardiovascular system.
The recent funding will propel Invizius into the next phase of clinical trials for H-Guard. This product is particularly aimed at continuous renal replacement therapy (CRRT), a type of dialysis used in intensive care units for patients with acute kidney injury. The stakes are high. Dialysis is a necessary evil for many, but it often comes with a host of complications. H-Guard seeks to change that narrative.
The immune system can be a double-edged sword. When blood comes into contact with the dialysis machine, it often reacts as if it’s encountering a foreign invader. This reaction can lead to inflammation, a response that can be life-threatening. H-Guard acts as a shield, coating the surfaces of the dialysis machine to prevent this immune response. It’s like putting on armor before entering battle.
Earlier this year, Invizius conducted a ‘First in Human’ study. The results were promising. The study demonstrated H-Guard’s safety and tolerability, along with encouraging biomarker data. This is a crucial milestone. It’s the first step in a long journey toward regulatory approval and widespread use.
The latest funding brings Invizius’s total raised to over £13 million. This is no small feat. It reflects the confidence investors have in the company’s vision and technology. The support from Calculus Capital, Syensqo, the University of Edinburgh’s Old College Capital, and Scottish Enterprise underscores the collaborative spirit of the Scottish biotech ecosystem.
Looking ahead, Invizius is gearing up for a Series B investment round early next year. This is where the stakes get even higher. The company aims to expand its research and development efforts, exploring additional benefits of H-Guard for patients. The potential is vast. If successful, H-Guard could redefine the standard of care for dialysis patients.
The urgency of this mission cannot be overstated. Dialysis can significantly reduce life expectancy. For many patients, it’s a matter of survival. The recent trials have shown that H-Guard has the potential to make a real difference. It’s not just about extending life; it’s about improving the quality of life.
Invizius’s journey is a testament to innovation in healthcare. The company is not just chasing profits; it’s pursuing a noble cause. The team, led by CEO Magnus Nicolson, is driven by a desire to save lives. Their commitment is palpable. Each trial, each study, is a step closer to a solution that could alleviate suffering for countless individuals.
The landscape of dialysis treatment is changing. H-Guard is at the forefront of this transformation. It represents hope for patients who have long endured the harsh realities of dialysis. The technology is not just a product; it’s a promise of better days ahead.
As Invizius prepares for its next clinical trials, the eyes of the medical community are watching closely. The implications of H-Guard extend beyond individual patients. They could reshape the entire approach to dialysis treatment. This is a pivotal moment in the field of nephrology.
In conclusion, Invizius’s recent funding is more than just a financial boost. It’s a lifeline for patients in need. The company’s innovative approach to addressing the challenges of dialysis is commendable. With H-Guard, Invizius is not just aiming to improve treatment; it’s striving to change lives. The journey is just beginning, but the destination is clear: a future where dialysis is safer and more effective. The road ahead may be long, but with each step, Invizius is paving the way for a brighter tomorrow.